# Finerenone and Renal Oxidative Stress

> **NCT06244758** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 91 (actual)

## Conditions studied

- Type2diabetes

## Interventions

- **DRUG:** Finerenone 20 MG Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06244758
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-18
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244758, "Finerenone and Renal Oxidative Stress". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06244758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*